Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 8/20 | 0.35 |
| ▸ | MAOA | P21397 | 7/20 | 0.35 |
| ▸ | MAOB | P27338 | 7/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6023453 | 1.00 | TRPA1 (0.43) | TRPA1SLC18A3SIGMAR1KDM1AMAOA | |
| SCHEMBL6023291 | 0.81 | KDM1A (0.34) | KDM1AMAOB | |
| SCHEMBL6023573 | 0.81 | MAP1LC3B (0.35) | KDM1AMAOAMAOB | |
| SCHEMBL6023577 | 0.81 | MAP1LC3B (0.35) | KDM1AMAOAMAOB | |
| SCHEMBL16892609 | 0.81 | TRPA1 (0.45) | TRPA1SLC18A3SIGMAR1AKR1C3AKR1C1 | |
| SCHEMBL6023447 | 0.77 | KMT2A (0.41) | KDM1AMAOAMAOBGAAMAPT | |
| SCHEMBL6023452 | 0.77 | KMT2A (0.41) | KDM1AMAOAMAOBGAAMAPT | |
| SCHEMBL9067468 | 0.71 | TRPA1 (0.46) | TRPA1SLC18A3SIGMAR1KDM1AMAOA | |
| SCHEMBL28653752 | 0.71 | OPRM1 (0.46) | TRPA1KDM1AMAOAMAOB | |
| SCHEMBL25053497 | 0.71 | TSHR (0.38) | TRPA1KDM1AMAOAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1867548-A | Preparation of 3-azabicyclo [3.1.0] hexane derivatives | PFIZER (US) | 2006-11-22 | — | — | CN | disclosed |
| US-7129263-B2 | Preparation of 3-azabicyclo [3.1.0] hexane derivatives | PFIZER INC. | 2006-10-31 | — | — | US | disclosed |
| US-20050113437-A1 | Preparation of 3-azabicyclo [3.1.0] hexane derivatives | PFIZER INC. | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113437-A1 | Preparation of 3-azabicyclo [3.1.0] hexane derivatives | ADH1C, ADH1A, ADH5 | TRPA1 3174/4885SLC18A3 1479/4885SIGMAR1 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.